Helixgate https://validator.w3.org/feed/docs/rss2.html Home White House policies are ‘incredibly worrisome’ for small biotechs, Rhythm CEO says  STAT+: Access granted: CMS greenlights more than 150 participants for chronic care experiment BioNTech, DualityBio tout ‘clinically meaningful’ efficacy for ADC in mid-stage endometrial cancer trial FDA narrows in on search for new biologics and vaccines leader Press Spyre drug for inflammatory bowel disease shows promise in early study Footer Revolution pancreatic cancer drug nearly doubles survival in key trial Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promise USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns Regeneron wades into radiopharma through $40M upfront deal with Telix Neural Mechanism Underlying Sensory Behavior Revealed in C. elegans STAT+: GSK advancing ovarian cancer drug mo-rez AbbVie enters world of pain in up to $715M deal with China’s Haisco Revolution Medicines’ pancreatic cancer drug doubles survival time in Phase 3 STAT+: Revolution Medicines touts ‘unprecedented’ data for pancreatic cancer pill Second rejection for tumor destroyer puts Replimune on a ‘challenging path’ STAT+: Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients Ideaya’s uveal melanoma drug exceeds success benchmark in late-stage trial Seaport, Hemab set sail for Nasdaq Rethinking dermatology trial design for late-stage success STAT+: Hospitals roll out chatbots, looking to reclaim their role in patients’ health conversations FDA flexibility isn’t absent but evolving regulations come with growing pains Seaport and Hemab file for IPOs, with Kailera expected to price soon Design of the biosensor-dependent coupling system stabilizes the high-synthesis phenotype of cell factory StockWatch: IPO Market Shows Sign of Life with Avalyn Filing GSK plans five Phase 3 studies for gynecological cancer ADC from Hansoh Life on Mars? Tiny cells just survived shock waves and toxic soil Opinion: Sports betting is creating a twofold public health crisis for some young men Opinion: What STAT readers think about nutrition education in med school More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and more A synthetic angiotensin II/ACE2-based hormone shunt controlling experimental hypertension Solar-driven biosynthesis of chemicals from phosphite-rich wastewater and carbon dioxide Hydrophobic tuning with non-canonical amino acids in a copper metalloenzyme Epigenetics at Birth Links Microbiome to Neurodevelopment, Potentially ASD and ADHD Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s push Bayer pharma executive predicts US-Europe price spreads will narrow Replimune’s advanced melanoma drug rebuffed by FDA for second time FDA rejects Replimune cancer therapy, saying company didn’t resolve trial doubts FDA again spurns Replimune melanoma drug Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge GAO report shows gap between scale of illegal vapes and enforcement  STAT+: Replimune skin cancer drug that became FDA flashpoint is rejected again Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option With oral obesity race underway, all eyes are on Lilly’s Foundayo launch Trump administration admits a glaring error in its accusations about New York health care fraud FDA rejects Replimune’s melanoma prospect for second time For AI To Have Impact, the Industry Must Align on Data STAT+: GSK says goodbye to leucovorin (again)